These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 23400746)

  • 21. Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans.
    Kim TH; Shin S; Landersdorfer CB; Chi YH; Paik SH; Myung J; Yadav R; Horkovics-Kovats S; Bulitta JB; Shin BS
    AAPS J; 2015 Sep; 17(5):1210-23. PubMed ID: 25990964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterizing the time-course of antihypertensive activity and optimal dose range of fimasartan via mechanism-based population modeling.
    Bulitta JB; Paik SH; Chi YH; Kim TH; Shin S; Landersdorfer CB; Jiao Y; Yadav R; Shin BS
    Eur J Pharm Sci; 2017 Sep; 107():32-44. PubMed ID: 28599987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of fimasartan, amlodipine, and rosuvastatin using partial replicated design in healthy adult subjects.
    Oh M; Ghim JL; Park SE; Kim EY; Shin JG
    Drug Des Devel Ther; 2018; 12():1157-1164. PubMed ID: 29780236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of multiple doses of fimasartan, an angiotensin II receptor antagonist, on the steady-state pharmacokinetics of digoxin in healthy volunteers.
    Yi S; Kim JW; Kim TE; Kim J; Jun YK; Choi J; Yoon SH; Cho JY; Song SH; Shin SG; Jang IJ; Yu KS
    Int J Clin Pharmacol Ther; 2011 May; 49(5):321-7. PubMed ID: 21543035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and metabolite profiling of fimasartan, a novel antihypertensive agent, in rats.
    Kim TH; Shin S; Bashir M; Chi YH; Paik SH; Lee JH; Choi HJ; Choi JH; Yoo SD; Bulitta JB; Ma E; Joo SH; Shin BS
    Xenobiotica; 2014 Oct; 44(10):913-25. PubMed ID: 24786684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PK/PD evaluation of fimasartan for the treatment of hypertension Current evidences and future perspectives.
    Angeli F; Verdecchia P; Trapasso M; Pane M; Signorotti S; Reboldi G
    Expert Opin Drug Metab Toxicol; 2018 May; 14(5):533-541. PubMed ID: 29676941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fimasartan: A New Angiotensin Receptor Blocker.
    Lee HY; Oh BH
    Drugs; 2016 Jul; 76(10):1015-22. PubMed ID: 27272555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and bioequivalence study of irbesartan tablets after a single oral dose of 300 mg in healthy Thai volunteers.
    Wittayalertpanya S; Chariyavilaskul P; Prompila N; Sayankuldilok N; Eiamart W
    Int J Clin Pharmacol Ther; 2014 May; 52(5):431-6. PubMed ID: 24725445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trial.
    Gu N; Kim BH; Lim KS; Kim SE; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2012 Jul; 34(7):1592-600. PubMed ID: 22727611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.
    Vavricka SR; Van Montfoort J; Ha HR; Meier PJ; Fattinger K
    Hepatology; 2002 Jul; 36(1):164-72. PubMed ID: 12085361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Rifampin-Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel.
    Schilling U; Dingemanse J; Voors-Pette C; Romeijn C; Dogterom P; Ufer M
    Clin Transl Sci; 2020 Sep; 13(5):886-890. PubMed ID: 32166864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PBPK modeling of irbesartan: incorporation of hepatic uptake.
    Chapy H; Klieber S; Brun P; Gerbal-Chaloin S; Boulenc X; Nicolas O
    Biopharm Drug Dispos; 2015 Nov; 36(8):491-506. PubMed ID: 26037524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validated LC-MS/MS Assay for the Quantitative Determination of Fimasartan in Human Plasma: Application to Pharmacokinetic Studies.
    Yoon SH; Oh S; Kim HS; Yi S; Yu KS; Jang IJ; Cho JY
    J Chromatogr Sci; 2015 Sep; 53(8):1250-6. PubMed ID: 25616988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1.
    Fan L; Zhang W; Guo D; Tan ZR; Xu P; Li Q; Liu YZ; Zhang L; He TY; Hu DL; Wang D; Zhou HH
    Clin Pharmacol Ther; 2008 Mar; 83(3):471-6. PubMed ID: 17851565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of the bifunctional modulator of angiotensin II type 1 receptor (AT1R) and PPARγ derived from the AT1R antagonist, Fimasartan.
    Choung W; Jung HJ; Nam EH; Yang D; Yoo B; Choi H; Lee BR; Park M; Jang SM; Lim JS; Kim KH; Chin J; Jung K; Lee G; Kim SH
    Bioorg Med Chem Lett; 2018 Oct; 28(19):3155-3160. PubMed ID: 30177375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data.
    Poirier A; Cascais AC; Funk C; Lavé T
    Chem Biodivers; 2009 Nov; 6(11):1975-87. PubMed ID: 19937834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic properties and bioequivalence of candesartan cilexetil in Korean healthy volunteers.
    Jeon JY; Im YJ; Kim Y; Han SM; Jo MJ; Shin DH; Yoo JS; Moon BK; Kim BK; Lee BH; Choi YH; Cho BS; Jang HY; Chae SW; Kim MG
    Drug Dev Ind Pharm; 2013 Sep; 39(9):1296-9. PubMed ID: 23030309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Organic anion transporting polypeptide-mediated transport of, and inhibition by, asunaprevir, an inhibitor of hepatitis C virus NS3 protease.
    Eley T; Han YH; Huang SP; He B; Li W; Bedford W; Stonier M; Gardiner D; Sims K; Rodrigues AD; Bertz RJ
    Clin Pharmacol Ther; 2015 Feb; 97(2):159-66. PubMed ID: 25670521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact on abiraterone pharmacokinetics and safety: Open-label drug-drug interaction studies with ketoconazole and rifampicin.
    Bernard A; Vaccaro N; Acharya M; Jiao J; Monbaliu J; De Vries R; Stieltjes H; Yu M; Tran N; Chien C
    Clin Pharmacol Drug Dev; 2015 Jan; 4(1):63-73. PubMed ID: 27128004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects.
    Luedtke D; Marzin K; Jungnik A; von Wangenheim U; Dallinger C
    Eur J Drug Metab Pharmacokinet; 2018 Oct; 43(5):533-541. PubMed ID: 29500603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.